Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval

Stock Information for Arch Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Arch Therapeutics Inc

Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
REPEAT - Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
Nutriband To Present at the Noble Capital Markets' Emerging Growth Virtual Equity Conference
11 Company Presentations Today at The MicroCap Rodeo Conference
Nutriband Inc. to Present at the MicroCap Rodeo Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.